Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand.

Clinical therapeutics - 1 Jul 2020

Chaivichacharn Piyawat, Avihingsanon Anchalee, Manosuthi Weerawat, Ubolyam Sasiwimol, Tongkobpetch Siraprapa, Shotelersuk Vorasuk, Punyawudho Baralee

Abstract excerpt

PURPOSE: Efavirenz exhibits high interindividual variability in plasma concentrations, leading to unpredictable efficacy and toxicity. Polymorphism of CYP2B6 516G > T has been found to predominantly contribute to efavirenz variability. However, dosage recommendations incorporating CYP2B6 516G > T polymorphism have not been investigated in the Thai population. This study aimed to develop a population model of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alkynes
Share to Anti-HIV Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzoxazines

Share to Cross-Sectional Studies

Share to Cyclopropanes

Share to Cytochrome P-450 CYP2B6

Share to Pharmacogenetics

Share to Thailand

Source

Identifiers

PMID: 32451120
DOI: 10.1016/j.clinthera.2020.04.013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand.PMID 32451120Read ↗

Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients.Semantic proximity Read ↗

Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients.Semantic proximity Read ↗

Dose Optimization of Efavirenz Based on Individual CYP2B6 Polymorphisms in Chinese Patients Positive for HIV.Semantic proximity Read ↗

CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population.Semantic proximity Read ↗

Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients.Semantic proximity Read ↗

Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIV-infected Thai children.Semantic proximity Read ↗

Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy.Semantic proximity Read ↗

Pharmacogenetics and clinical biomarkers for subtherapeutic plasma efavirenz concentration in HIV-1 infected Thai adults.Semantic proximity Read ↗

High plasma efavirenz concentration and CYP2B6 polymorphisms in Thai HIV-1 infections.Semantic proximity Read ↗

CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe.Semantic proximity Read ↗

Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients.Semantic proximity Read ↗

Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.